Examples of using Zerbaxa in English and their translations into Swedish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Your doctor may need to reduce the dose of Zerbaxa or decide how often Zerbaxa is given to you.
Zerbaxa may cause dizziness,
mucus during or after treatment with Zerbaxa.
Efficacy has been demonstrated in clinical studies against the pathogens listed under each indication that were susceptible to Zerbaxa in vitro.
blood test(called Coombs test) tell your doctor that you are having or have recently had Zerbaxa.
Infections caused by bacteria that are not sensitive to Zerbaxa or caused by a fungus can occur during or following treatment with Zerbaxa.
The CHMP considered that Zerbaxa had been shown to be effective at curing infections in the patients studied,
Zerbaxa successfully treated the infection in about 85% of the cases where it was given(288 of 340),
stop or avoid Zerbaxa therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for you.
pooled Phase 3 trials) occurring in patients receiving Zerbaxa were nausea,
What are the risks associated with Zerbaxa?
Zerbaxa is available as a powder for preparing a solution for infusion(drip)
Zerbaxa must not be used in people who are hypersensitive(allergic)
Zerbaxa was evaluated in Phase 3 comparator-controlled clinical trials of complicated intra-abdominal infections
Table 1: Intravenous dose of Zerbaxa by type of infection in patients with creatinine clearance.
Zerbaxa 1 g/ 0.5 g powder for concentrate ceftolozane/ tazobactam.
Zerbaxa 1 g/ 0.5 g powder for concentrate for solution for infusion ceftolozane/ tazobactam.
Zerbaxa 1 g/0.5 g powder for concentrate for solution for infusion.
Zerbaxa is for intravenous infusion.
Zerbaxa was compared with another antibiotic, meropenem.